twk-12 Antibody

Overview of TWEAK/TNFSF12 Antibody

TWEAK (TNF-related weak inducer of apoptosis), encoded by the TNFSF12 gene, is a type II transmembrane protein in the TNF superfamily. It plays roles in apoptosis, inflammation, and angiogenesis . Antibodies targeting TWEAK are critical for studying its interaction with receptors like TNFRSF12A (TWEAK R/Fn14) and its downstream signaling pathways .

Mechanistic Insights

• Apoptosis Regulation: TWEAK antibodies block TWEAK-TWEAK R interactions, reducing NF-κB activation and apoptosis in endothelial cells .

• Angiogenesis Modulation: TWEAK antibodies inhibit endothelial cell proliferation and migration, critical in cancer and inflammatory diseases .

• Structural Epitopes: Antibody-antigen binding involves aromatic residues (e.g., tryptophan, tyrosine) in complementarity-determining regions (CDRs), contributing to high specificity .

Validation Data

• Western Blot: Detects TWEAK at ~30 kDa under reducing conditions .

• Neutralization Efficacy: IC₅₀ values range from 0.1–1.0 μg/mL in cell-based assays .

Production and Validation

TWEAK antibodies are typically generated via hybridoma technology :

1. Immunization: Human Ig transgenic mice immunized with recombinant TWEAK antigen .

2. Hybridoma Screening: Clones selected for high affinity (KD < 1 nM) and specificity .

3. Characterization: Validated via ELISA, surface plasmon resonance (SPR), and functional assays .

Comparative Analysis of TWEAK Antibodies

Clinical and Therapeutic Relevance

• Autoimmune Diseases: TWEAK antibodies show potential in rheumatoid arthritis and lupus models by reducing pro-inflammatory cytokines .

• Cancer: Targeting TWEAK R inhibits tumor angiogenesis in hepatocellular carcinoma .

Limitations and Future Directions

• Species Specificity: Most antibodies target murine TWEAK; humanized versions are under development .

• Functional Redundancy: TWEAK shares pathways with TNF-α, necessitating combination therapies .